应用技术服务及相关技术解决方案

Search documents
汉邦科技8月26日获融资买入2154.27万元,融资余额8638.29万元
Xin Lang Cai Jing· 2025-08-27 02:12
Group 1 - The core viewpoint of the news is that Hanbang Technology experienced a stock price increase of 1.63% on August 26, with a trading volume of 135 million yuan [1] - On the same day, Hanbang Technology had a financing purchase amount of 21.54 million yuan and a net financing purchase of 10.17 million yuan, with a total financing and securities balance of 86.38 million yuan [1] - The financing balance of Hanbang Technology accounts for 9.64% of its circulating market value [1] Group 2 - As of June 30, 2025, Hanbang Technology's revenue for the first half of the year was 349 million yuan, representing a year-on-year growth of 5.99% [1] - The net profit attributable to the parent company for the same period was 27.80 million yuan, showing a year-on-year decrease of 26.24% [1] - The number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [1] Group 3 - The largest circulating shareholder of Hanbang Technology as of June 30, 2025, is Dongfanghong Medical Upgrade Stock Initiation A, holding 483,700 shares as a new shareholder [2]
C汉邦获融资净买入4176.33万元
Zheng Quan Shi Bao Wang· 2025-05-19 01:52
Core Viewpoint - C Hanbang (688755) experienced a significant increase of 102.46% on its first trading day, with a turnover rate of 75.65% and a transaction volume of 609 million yuan [2]. Group 1: Company Overview - C Hanbang is a high-tech enterprise focused on chromatography technology, integrating research and development, production, and sales. The company primarily provides professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [2]. Group 2: Market Performance - On its debut, C Hanbang's financing buy-in amounted to 49.50 million yuan, accounting for 8.13% of the total trading volume. The latest financing balance stands at 41.76 million yuan, representing 5.48% of the circulating market value [2]. - The stock attracted a net inflow of 210 million yuan from major funds on its first day, with large orders contributing a net inflow of 81.52 million yuan and big orders contributing 129 million yuan [2].
N汉邦开盘上涨115.20%
Zheng Quan Shi Bao Wang· 2025-05-16 02:03
Company Overview - N Hanbang has been listed today with an opening price of 49.00 yuan, representing an increase of 115.20% from its issue price [2] - The company focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, application technology services, and related technical solutions [2] Financial Highlights - The total number of shares issued by the company is 22 million, with an online issuance of 7.04 million shares at an issue price of 22.77 yuan per share [2] - The issue price corresponds to a price-to-earnings (P/E) ratio of 26.35, compared to the industry average P/E ratio of 28.04 [2] - The total funds raised from the initial public offering (IPO) amount to 501 million yuan, which will be used for working capital, the construction of a chromatography separation equipment R&D center, and the production projects for laboratory chromatography separation and purification instruments [2] Recent IPO Performance - N Hanbang's first-day performance is notable, with a significant increase of 115.20% [2] - Other recent IPOs on the same day include N Zairun, which saw a rise of 98.12%, and Tian Gong Co., which experienced a dramatic increase of 458.63% [3]
汉邦科技明日申购 5.00万市值可顶格申购
Zheng Quan Shi Bao Wang· 2025-05-06 06:58
Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, providing professional separation and purification equipment, consumables, application technology services, and related technical solutions primarily for the pharmaceutical and life sciences sectors [1]. IPO Details - The company is set to launch its public offering with a total share capital of 66 million shares, of which 22 million shares will be publicly issued, representing 25% of the post-issue total share capital [1]. - The issue price is set at 22.77 yuan per share, with an earnings per share (EPS) ratio of 26.35 times, compared to the industry average of 28.04 times [1]. - The maximum subscription limit for a single account is 5,000 shares, requiring a minimum market value of 50,000 yuan in the Shanghai market for top-tier subscriptions [1]. Fundraising Allocation - The funds raised will be allocated to several projects, including: - Production project for 1,000 units of liquid chromatography series separation equipment (193.03 million yuan) - Construction of a chromatography separation equipment R&D center (271.10 million yuan) - Production project for 2,000 units of laboratory chromatography separation and purification instruments (224.76 million yuan) - Supplementing working capital (291.11 million yuan) [1]. Financial Performance - Key financial indicators for Hanbang Technology include: - Total assets for 2024 are projected at 1.32 billion yuan, a decrease from 1.35 billion yuan in 2023 and 1.40 billion yuan in 2022 [1]. - Net assets have increased to 739.63 million yuan in 2024 from 638.37 million yuan in 2023 and 566.92 million yuan in 2022 [1]. - Operating revenue is expected to reach 690.88 million yuan in 2024, up from 619.01 million yuan in 2023 and 481.79 million yuan in 2022 [1]. - Net profit attributable to shareholders is projected at 79.34 million yuan for 2024, compared to 51.50 million yuan in 2023 and 38.56 million yuan in 2022 [1]. - Basic and diluted earnings per share are both expected to be 1.20 yuan in 2024, up from 0.78 yuan in 2023 and 0.62 yuan in 2022 [1]. - The weighted average return on equity is projected at 11.51% for 2024, an increase from 8.55% in 2023 and 9.86% in 2022 [1]. - Net cash flow from operating activities is expected to be 129.88 million yuan in 2024, compared to 113.33 million yuan in 2023 and 19.84 million yuan in 2022 [1]. - R&D investment is projected at 41.85 million yuan in 2024, representing 6.06% of operating revenue, consistent with previous years [1].
色谱设备龙头汉邦科技启动招股:市占率领先 持续创新引领高端突破
Zheng Quan Ri Bao Wang· 2025-04-24 07:42
与此同时,近年来,为加速我国医药工业和科研仪器设备领域的发展,国家有关部门先后出台多项政策 和法规,加大产业扶持力度,推动产业发展。2021年以来,《"十四五"医药工业发展规划》《"十四 五"生物经济发展规划》《国民经济和社会发展第十四个五年规划和2035年远景目标纲要》等产业支持 政策的发布,明确了制药装备行业和科研仪器设备行业自主、创新的发展方向。上述政策和法规的发布 和落实,为产业提供了财政、税收、技术和人才等多方面支持,为包括汉邦科技在内的业内企业创造了 良好的经营环境。 4月23日晚,江苏汉邦科技股份有限公司(股票简称"汉邦科技",股票代码"688755")披露首次公开发行股 票招股意向书、首次公开发行股票发行安排及初步询价公告等文件,正式启动招股。根据发行安排,公 司网上、网下申购日为2025年5月7日。 政策支持+市场需求激增行业龙头业绩稳健增长 汉邦科技是一家以色谱技术为核心,集研发、生产和销售于一体的高新技术企业,主要为制药、生命科 学等领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。作为最早拥有完整自 主知识产权的液相色谱系统的国产厂商之一,汉邦科技自主研发产品涵盖从实 ...